PROBLEM TO BE SOLVED: To obtain a new (activated) modified blood coagulation factor VII which has a modification at a specific site of an amino acid sequence, has an enhanced enzyme activity, and is useful as a medicine effective for treating a hemophilia inhibitor patient or the like. SOLUTION: This is a new (activated) modified blood coagulation factor VII (FVII) which has at least one modification(s) selected from a group comprising cleaving the disulfide bond (159Cys-164Cys) consisting of 159th cysteine (159Cys) and 164th cysteine (164Cys) in blood coagulation factor VII, substituting, adding, or deleting at least a part of the amino acid sequence constituting the loop structure consisting of the amino acid sequence from 233rd threonine (233Thr) to 240th asparagine (240Asp) in FVII, and substituting, adding, or deleting at least a part of the amino acid sequence constituting the intervening sequence consisting from 304th arginine (304Arg) to 329th cysteine (329Cys) in FVII, and has an enhanced enzyme activity.
展开▼
